Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

14.24 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Navigating 6 Analyst Ratings For Viridian Therapeutics
Via Benzinga
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Analyst Ratings for Viridian Therapeutics
Via Benzinga
Where Viridian Therapeutics Stands With Analysts
Via Benzinga
Analyst Ratings for Viridian Therapeutics
Via Benzinga
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering. 
Via Benzinga
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
From Viridian Therapeutics, Inc.
Via Business Wire
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 647 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 406 companies made new 52-week lows. 
Via Benzinga
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
From Viridian Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.